Start Submission Become a Reviewer

Reading: World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Pati...

Download

A- A+
Alt. Display

Expert Consensus Document

World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI

Authors:

Glenn N. Levine,

Baylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, Texas, US
X close

Young-Hoon Jeong,

Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, KR
X close

Shinya Goto,

Department of Medicine (Cardiology), Tokai University School of Medicine, Tokyo, JP
X close

Jeffrey L. Anderson,

Intermountain Medical Center, University of Utah School of Medicine, Salt Lake City, Utah, US
X close

Yong Huo,

Department of Cardiology, Peking University First Hospital, Beijing, CN
X close

Jessica L. Mega,

Brigham and Women’s Hospital, TIMI Study Group, Boston, Massachusetts, US
X close

Kathryn Taubert,

World Heart Federation, Geneva, CH
X close

Sidney C. Smith Jr.

Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina, US
X close

Abstract

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes and in those undergoing percutaneous coronary intervention (PCI) have been formulated by both the ACC/AHA and the ESC. These recommendations are based primarily on large, phase III, randomized, controlled trials of the P2Y12 inhibitors clopidogrel, prasugrel, and ticagrelor. However, few East Asian patients have been included in the trials to assess the use of these agents, particularly the newer agents prasugrel and ticagrelor. Additionally, an increasing body of data suggests that East Asian patients have differing risk profiles for both thrombophilia and bleeding compared with white patients, and that a different ‘therapeutic window’ of on-treatment platelet reactivity might be appropriate in East Asian patients. Furthermore, a phenomenon referred to as the ‘East Asian paradox’ has been described, in which East Asian patients have a similar or even a lower rate of ischaemic events after PCI compared with white patients, despite a higher level of platelet reactivity during DAPT. Recognizing these concerns, the World Heart Federation has undertaken this evidence-based review and produced this expert consensus statement to determine the antiplatelet treatment strategies that are most appropriate for East Asian patients.

How to Cite: Levine GN, Jeong Y-H, Goto S, Anderson JL, Huo Y, Mega JL, et al.. World Heart Federation Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI. Global Heart. 2014;9(4):457–67. DOI: http://doi.org/10.1016/j.gheart.2014.08.001
11
Views
14
Downloads
20
Citations
Published on 01 Dec 2014.

Downloads

  • PDF (EN)

    comments powered by Disqus